Below are the most recent publications written about "Lipopeptides" by people in Profiles.
-
Grisanti LA, Thomas TP, Carter RL, de Lucia C, Gao E, Koch WJ, Benovic JL, Tilley DG. Pepducin-mediated cardioprotection via ?-arrestin-biased ?2-adrenergic receptor-specific signaling. Theranostics. 2018; 8(17):4664-4678.
-
Chaturvedi M, Schilling J, Beautrait A, Bouvier M, Benovic JL, Shukla AK. Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors. Trends Biochem Sci. 2018 07; 43(7):533-546.
-
Panettieri RA, Pera T, Liggett SB, Benovic JL, Penn RB. Pepducins as a potential treatment strategy for asthma and COPD. Curr Opin Pharmacol. 2018 06; 40:120-125.
-
Hiwatashi N, Kraja I, Benedict PA, Dion GR, Bing R, Rousseau B, Amin MR, Nalband DM, Kirshenbaum K, Branski RC. Nanoparticle delivery of RNA-based therapeutics to alter the vocal fold tissue response to injury. Laryngoscope. 2018 05; 128(5):E178-E183.
-
Carr R, Schilling J, Song J, Carter RL, Du Y, Yoo SM, Traynham CJ, Koch WJ, Cheung JY, Tilley DG, Benovic JL. ?-arrestin-biased signaling through the ?2-adrenergic receptor promotes cardiomyocyte contraction. Proc Natl Acad Sci U S A. 2016 07 12; 113(28):E4107-16.
-
Mattioni J, Portnoy JE, Moore JE, Carlson D, Sataloff RT. Laryngotracheal mucormycosis: Report of a case. Ear Nose Throat J. 2016 Jan; 95(1):29-39.
-
Quoyer J, Janz JM, Luo J, Ren Y, Armando S, Lukashova V, Benovic JL, Carlson KE, Hunt SW, Bouvier M. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A. 2013 Dec 24; 110(52):E5088-97.
-
Doria C, Bodzin AS, Vaccino S, Daskalakis C, Krawitz S, Ramirez CB. A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver function tests while on caspofungin. Clin Transplant. 2011 Jul-Aug; 25(4):569-75.
-
Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother. 2004 Nov; 48(11):4306-14.
-
Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother. 2002 Mar; 46(3):739-45.